US Patent

US10238643 — Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation

Formulation · Assigned to Puretech Health LLC · Expires 2030-07-21 · 4y remaining

Vulnerability score 61/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects methods and compositions for treating CNS disorders using combinations of muscarinic activators and inhibitors.

USPTO Abstract

Methods for the treatment of CNS disorders using combinations of muscarinic activators and inhibitors, and medicaments comprising muscarinic activators and inhibitors.

Drugs covered by this patent

Patent Metadata

Patent number: US10238643
Jurisdiction: US
Classification: Formulation
Expires: 2030-07-21
Drug substance claim: No
Drug product claim: Yes
Assignee: Puretech Health LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.